Close this search box.

We are creating some awesome events for you. Kindly bear with us.

The Value of IP for MedTech

If you’ve ever had a bone fracture or had to get burr holes, I guarantee you’d wish you’d known this product much sooner.

Founded in late 2003, by Dr Teoh Swee Hin, Osteopore is a Singaporean medical device manufacturer specialising in 3D printed biomimetic, bioresorbable implants. The implants are used to heal bone fractures and/or cover trephination burr holes in neurosurgery. Clinical trials show that the implant encourages bone growth and remodelling.

Not a Fad, But a First

In our interview with Dr Lim, the Chief Technology Officer of Osteopore, shared that the impetus behind 3D printing the implants.

“The reason why we went into 3D printing was because we wanted to achieve a certain microstructure that resembles bone. And the only manufacturing tool that allowed us to do that was 3D printing. That was why we went into 3D, not because it was the hype – because it wasn’t 20 years ago.”

Thanks to 3D printing, the team was able to create a biomimetic structure, or a structure that looks like bone. In turn, blood vessels and tissue can go into scaffolds and not just around it, critical in the healing process. Since the implant populates the entire space inside the scaffold, over time, the scaffold will be dissolved into carbon dioxide and water within the body. After two years, the patient will no longer have the implant. What is left are their own bone and tissue structures.

The innovative technology behind Osteopore’s products make the implants the first of its kind in the world.

“I think it is the only technology that allows our patients to heal this way,” said Dr Lim.

Certified for More

For products with a foreseeably huge demand, relevant authorities have steadily been giving it their mark of approval.

“We achieved our US FDA clearance in 2006…We have been teamed up with the European Authorities since 2009. Our products are approved in more than 12 other countries around the world. In terms of hospital outreach, we have about 80 to 100 hospitals globally that use our product on a routine basis,” said Dr Lim.

This is a major feat for a homegrown MedTech company.

“All the technology is developed in Singapore. There was no foreign involvement in our technology… It is very rare for a high-risk device like ours to be operating out of Singapore and be global at the same time. Not like your traditional US or maybe Europe that has an office here. It is the other way around actually,” beamed Dr Lim.

The Need for Intellectual Property in MedTech

Truly something to be proud of, the company is cognisant of the need for building a brand and credibility in the medical industry through intellectual property (IP).

According to Dr Lim, brand building through IP is only the first step. What’s more important in the medical device field is to create something which is trustworthy. Both the product and the technology underpinning it must be able to inspire trust. This according to Dr Lim, is what makes brand building more sustainable and stable.

“Being able to protect the company’s technology with suitable IP allows us to create this brand that our products are safe for use, reliable – it gives a consistent outcome,” states the CTO.

Thus, there should be a more all-encompassing view of IP that goes beyond just patents, trademarks and trade secrets.

“As long as anyone uses Osteopore, they would understand where we are from, the technologies that we have, that we are a trust worthy partner for them. That gives confidence not just to the hospital, but also to the patients and the surgeons that receive the implants.”

A New Diagnosis for IP in Industry 4.0?

When asked if the disruptions in Industry 4.0 are changing how MedTech companies understand IP rights, Dr Lim was not short of conviction.

“Yes, of course, especially if we are looking at delivering devices at the point of care.”

Traditionally, there would be a couple manufacturing locations to distribute medical devices, especially for implants. Deliveries need to be efficient and cost effective, without unintentionally tampering with the product. Moreover, individual products must pass quality approval before they are distributed.

Dr Lim thinks these processes will look different in Industry 4.0.

“When you have Industry 4.0, we are trying to do a little “Grab” or “Uber”, which is to supply on demand. The intellectual property rights associated with this business model would then change drastically. Because now you are going to be sending information through a digital network into a remote location. And the intellectual property rights which are associated with this business model will actually be associated with the information that is [sent] across.”

The data and the process by which it is transmitted is most valuable. Utilising a cloud-based system to improve the accuracy of the supply chain manufacturing and logistics is key. Protecting data is equally as important, if not more valuable than the business processes it would seem.

Referencing this, Dr Lim says, “I think the IP is all there. That is why it has changed a little bit from the traditional understanding of IP being something which you hold very closely to the company or in secrecy within the company.”

Whatever Industry 4.0 brings to the MedTech field, Dr Lim and his team are relooking how to restructure the company’s IP protection and improve the technology behind their product.

“We continue to work with universities in Singapore to develop the technology…We are proud to be leading the world in this.”


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.